Skip to main content

Advertisement

Table 3 Sensitivity analysis parameters

From: Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China

Parameter One-way sensitivity analysis PSA
Base case value Range SD Distribution
FOLFOX4 survival (PFS and OS) 100% 80–120% 20% Normal
Sorafenib survival (PFS and OS) 100% 80–120% 20% Normal
Sorafenib monthly cost 3777 3021–4532 1126 Gamma
FOLFOX4 monthly cost 1865 1492–2238 373 Gamma
Dosage per cycle Oxaliplatin 138 110–166 28 Normal
Dosage per cycle 5-FU 3247 2597–3896 649 Normal
Dosage per cycle L-FC 649 519–779 130 Normal
Utility PFS 0.76 0.61–0.91 0.152 Normal
Utility PD 0.68 0.54–0.82 0.136 Normal
General ward cost per cycle 39 19–78 8 Gamma
AE costs 100% 50/200% 20% Gamma
Cost of HCC progression test (RMB) 155 78–310 93 Gamma
Proportion of FOLFOX4 general ward 100% 50% N/A N/A
Discount rate 5% 0–8% N/A N/A